Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Scilipoti

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
BJU International|March 26, 2025
The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidatesMario de Angelis, Pietro Scilipoti, Alfonso Santangelo, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
European Urology Oncology|June 24, 2026
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter AnalysisAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
BJU International|March 26, 2025
The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidatesMario de Angelis, Pietro Scilipoti, Alfonso Santangelo, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
European Urology Oncology|June 24, 2026
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter AnalysisAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
Pageof 10